Wed, November 27, 2024
Tue, November 26, 2024
Mon, November 25, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Sat, June 10, 2017
Sat, June 3, 2017
Wed, May 31, 2017
Wed, May 17, 2017
Fri, May 12, 2017
Thu, May 11, 2017
Tue, May 9, 2017
Thu, May 4, 2017
Thu, April 20, 2017
Fri, April 14, 2017
Thu, March 23, 2017
Fri, March 17, 2017
Thu, March 9, 2017
Sat, March 4, 2017
Fri, March 3, 2017
Thu, March 2, 2017
Wed, February 15, 2017
Mon, February 13, 2017
Wed, February 8, 2017
Thu, February 2, 2017
Fri, January 13, 2017
Wed, January 11, 2017
Wed, January 4, 2017
Fri, December 16, 2016
Thu, December 15, 2016
Mon, December 12, 2016
Thu, December 8, 2016
Wed, November 23, 2016
Mon, November 14, 2016
Sun, November 13, 2016
Wed, November 9, 2016
Thu, November 3, 2016
Wed, November 2, 2016
Mon, October 17, 2016
Sat, October 8, 2016
Thu, October 6, 2016
Wed, October 5, 2016
Mon, October 3, 2016
Fri, September 30, 2016
Thu, September 29, 2016
Tue, September 27, 2016
Mon, September 26, 2016
Fri, September 23, 2016
Thu, September 22, 2016
Wed, September 21, 2016
[ Wed, Sep 21st 2016 ] - Market Wire
Last Patient Out
Tue, September 20, 2016
Mon, September 19, 2016
Sun, September 18, 2016
Fri, September 16, 2016
Thu, September 15, 2016
Wed, September 14, 2016
Mon, September 12, 2016
Fri, September 9, 2016
Thu, May 9, 2013
[ Thu, May 09th 2013 ] - Market Wire
Achieves Record Revenues
Wed, May 8, 2013
Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013

Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ (lorcaserin HCl) for Chronic Weight Management


//health-fitness.news-articles.net/content/2013/ .. orcaserin-hcl-for-chronic-weight-management.html
Published in Health and Fitness on Tuesday, May 7th 2013 at 12:45 GMT by Market Wire   Print publication without navigation


Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ (lorcaserin HCl)... -- SAN DIEGO, May 7, 2013 /PRNewswire/ --

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: [ ARNA ]) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ(pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal Register. Following the effective date, BELVIQ will be available to patients in the United States by prescription, and Arena will receive $65 million in milestone payments from Eisai Inc. under their marketing and supply agreement.

BELVIQ is approved for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). The indication includes the following limitations of use: The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss and the effect of BELVIQ on cardiovascular morbidity and mortality have not been established.

"We are thrilled that BELVIQ will soon be available in the United States as a new treatment option for the medical management of patients who are overweight with a comorbidity or obese," said Jack Lief, Arena's President and Chief Executive Officer.

Eisai is responsible for the marketing and distribution of BELVIQ in the United States. Arena manufactures BELVIQ at its facility in Switzerland, and sells finished commercial product to Eisai for a purchase price starting at 31.5% of Eisai's annual net product sales. The purchase price increases on a tiered basis up to 36.5% on the portion of annual net product sales exceeding $750 million. Arena is also eligible to receive $1.16 billion in purchase price adjustment payments based on annual net sales levels of BELVIQ.

About BELVIQ (lorcaserin HCl)

BELVIQ is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. The exact mechanism of action of BELVIQ is not known.

IMPORTANT SAFETY INFORMATION

Contraindication

  • BELVIQ should not be taken during pregnancy or by women who are planning to become pregnant.

Warnings and Precautions

  • BELVIQ is a serotonergic drug. The development of potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors), dextromethorphan, lithium, tramadol, antipsychotics or other dopamine antagonists, particularly when used in combination. Patients should be monitored for the emergence of serotonin syndrome symptoms or NMS-like reactions, including agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting, diarrhea, and muscle rigidity. Treatment with BELVIQ and any concomitant serotonergic or antidopaminergic agents should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.
  • Patients should not take BELVIQ in combination with drugs that have been associated with valvular heart disease (e.g., cabergoline). In clinical trials, 2.4% of patients taking BELVIQ and 2.0% of patients taking placebo developed valvular regurgitation: none of these patients was symptomatic. BELVIQ should be used with caution in patients with congestive heart failure (CHF). Patients who develop signs and symptoms of valvular heart disease, including dyspnea, dependent edema, CHF, or a new cardiac murmur, should be evaluated and discontinuation of BELVIQ should be considered.
  • Impairment in attention, memory, somnolence, confusion, and fatigue, have been reported in patients taking BELVIQ. Patients should not drive a car or operate heavy machinery until they know how BELVIQ affects them.
  • The recommended dose of 10 mg twice daily should not be exceeded, as higher doses may cause euphoria, hallucination, and dissociation. Monitor patients for the development or worsening of depression, suicidal thoughts or behaviors, and/or any changes in mood. Discontinue BELVIQ in patients who develop suicidal thoughts or behaviors.
  • Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus who are being treated with antidiabetic medications, so measurement of blood sugar levels before and during treatment with BELVIQ is recommended. Decreases in doses of antidiabetic medications or changes in medication regimen should be considered.
  • Men who experience priapism should immediately discontinue BELVIQ and seek emergency medical attention. BELVIQ should be used with caution with erectile dysfunction medications. BELVIQ should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease).
  • Because BELVIQ may cause a slow heartbeat, it should be used with caution in patients with a history of bradycardia or heart block greater than first degree.
  • Consider monitoring for CBC changes, prolactin excess, and pulmonary hypertension.

Most Common Adverse Reactions

  • In patients without diabetes: headache (17%), dizziness (9%), fatigue (7%), nausea (8%), dry mouth (5%), and constipation (6%).
  • In patients with diabetes: hypoglycemia (29%), headache (15%), back pain (12%), cough (8%), and fatigue (7%).

Nursing Mothers

  • BELVIQ should not be taken by women who are nursing.

For more information about BELVIQ, [ click here ] for the full Product Information or visit [ www.BELVIQ.com ].

About Arena Pharmaceuticals

Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, is approved in the United States, and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at [ www.arenapharm.com ].

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

About Eisai Inc.

At Eisai Inc., human health care is the goal. Eisai gives its first thoughts to patients and their families, and helping to increase the benefits health care provides. As the US pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., Eisai's passionate commitment to patient care is the driving force behind its efforts to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Eisai's key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit [ www.eisai.com/US ]. 

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, selectivity, mechanism of action, scheduling, launch and availability of BELVIQ; the potential of BELVIQ, including in providing a new treatment option; rights, obligations, payments, expectations and future activities related to the agreement with Eisai; regulatory filings, review and approval of BELVIQ; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability of BELVIQ and pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever by any other regulatory agency; regulatory decisions in one territory may impact regulatory decisions in other territories and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo Partners



Cindy McGee, Vice President,

David Schull, President

Investor Relations & Alliance Management

[ david.schull@russopartnersllc.com ]

[ cmcgee@arenapharm.com

858.717.2310

858.453.7200, ext. 1479


 

SOURCE Arena Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.arenapharm.com ]

Publication Contributing Sources